

## Management of a mild COVID-19 infection through Ayurvedia and yogaintervention : a case study.

Swati S. jawade<sup>1\*</sup>, Tirunagiri Swamy<sup>2</sup>, Anil Kale<sup>3</sup>. 1 PG Scholar, Kaumarbhirtya, GAC Osmanabad. 2 Hod and Professor, Kaumarbhritya Dept, R.A. Potdar, Mumbai.

3 Hod and Professor, Kaumarbhritya Dept, GAC Osmanabad. Corresponding Author: Dr. Swati S. jawade PG Scholar, Kaumarbhritya Dept. GAC Osmanabad.

Submitted: 10-10-2022

Accepted: 21-10-2022 \_\_\_\_\_

#### **ABSTRACTS :-**

The COVID-19 pandemic has posed an immense challenge to health care systems around theglobe in terms of limited health care facilities and proven medical therapeutics to address the symptoms of the infection. The current health care strategies have primarily focused on either the pathogen on the environmental factors. However, efforts towards strengthening the host immunity are important from public health perspective to prevent the spread of infection and downregulate the potency of the agent. While a vaccine can induce specific immunity in the host, non-specific ways of improving overall host immunity are the need. This scenario has paved theway for the use of traditional Indian therapies such as Ayurveda and Yoga. This review aims atcollating available evidence on Ayurveda, Yoga and COVID-19. Further, it draws inferences from recent studies on Yoga and Ayurveda on immunity, respiratory health and mental healthrespectively to approximate its probable role in prophylaxis and as an add-on management optionfor the current pandemic.

\_\_\_\_\_

#### **KEYWORDS:**

Agni, Ayurveda, Janapadodhwamsa, yoga, COVID-19.

#### **INTRODUCTION :-**I.

The COVID-19 pandemic has become a major global challenge, especially for the Health care sector. In the current situation where the number of positive cases of COVID-19 is outstripping existing healthcare facilities, an economically feasible therapeutic option is of critical importance. Strategies that can improve immune surveillance and resilience in terms ofreduction in inflammatory markers and improvement in the activity of the specific immune cellsinvolved in the pathogenesis of COVID-19 is the need of the hour. Conti et al, suggested that reduction of inflammatory responses is a relevant strategy to reduce the severity of the

COVID-19 disease, which could potentially reduce the number of cases requiring critical care . Thecurrent health care strategies have primarily focussed on either the pathogen or on theenvironmental factors. However, the efforts towards strengthening the host immunity are important from public health perspective to prevent the spread of infection and downregulate thepotency of the agent. While a vaccine can induce specific immunity to the host , nonspecificways of improving overall host immunity are the need of the hour. Thus, traditional Indiansystems of medicine such as Ayurveda and Yoga should be explored for their potential role inimproving host immunity and reducing severity of the infection.

This review aims at consolidating the existent literature available on Yoga and Ayurveda for COVID-19. Further, it infers the ancilliary evidences for utlity of Yoga and Ayurveda in enhancing health in three major domains: 1) Immune system, 2) Respiratory system and

3)Mental health, that are more vulnerable during COVID-19 infection.

Mild to moderate (mild symptoms up to mild pneumonia): 81%

Severe (dyspnea, hypoxia, or >50% lung involvement on imaging): 14%

Critical (respiratory failure, shock, or multiorgan system dysfunction): 5%

#### **Understanding COVID-19 Ayurveda Perspective**

According to Ayurveda classics, the term Janapadodhwamsa (epidemic diseases) has been usedto describe epidemics/pandemics which manifest due polluted vayu to (air), bhumi(land),jala(water) and kala (vitiated seasons). sushrutta has also described a condition that mimics all symptoms of an influenza-like illness

DOI: 10.35629/7781-070512111219 | Impact Factor value 7.429 | ISO 9001: 2008 Certified Journal Page 1211



suchas the current COVID-19 .jwara (fever), swasa(difficulty in breathing), kasa(cough), shiroruk(head ache), pratisyaya (common cold), gandhaajnana (anosmia), bhrama (giddiness/postural instability), and vamathu (vomiting) [6]. disease involving all tridosa h in its pathophysiology which has been described in Ayurveda as difficult to cure) [4]. **Yoga Perspective** Yoga therapy emphasises on modulation of bactor such as regulation and moderation of

of host factors such as regulation and moderation of the lifestyle factors [8]. Host immunity is downregulated due to altered lifestylepatterns such as consumption of unwholesome food, physical inactivity, improper sleep-wakecycle, increase in workload, stress and addictions [9,10]. This results in fragility of the immuneresilience that makes the host succumb to the virulence of the virus. Thus, the aim of Ayurvedaand Yoga therapeutics is to enhance host immunity and reduce the extent of infection and inflammation in the body by balancing body humors and lifestyle factors.

# Potential Role of Ayurveda and Yoga in COVID-19 Infection: Current Evidence Base

To understand the role, we have categorized our literature search into three domains which are commonly involved in COVID-19 infection:

1) Immune system,

2) Respiratory System and

3)Mental Health

Presentation of clinical sy	mptoms in COVID-19.			
TYPICAL SYMPTOMS COMPLICATIONS	EARLY			LATE
MAJOR	Fever (83-99%), Cough (59-82%)	Breathing Difficulty (( 40%), M Pneumonia.	31- Iild	Hypoxia, Pneumonia, ARDS, Coagulopathy
COMMON	Chills Repeated shaking with chills Myalgia Headache Sore throat New loss of taste or smell			
ASSOCIATED	Anorexia (40-84%)   Fatigue (44-70%)   Sputum (28-33%) (28-33%)			
ATYPICAL SYMPTOMS				
SPORADIC	< 10% Confusion Haemoptysis Vomiting Nausea Diarrhoea			
Being Investigated				
RARE	Skin eruptions			




### Analysis of clinical symptoms of a cluster of COVID-19 patients.

Patient No.	Age	Sex	Baseline	Clinical course	Test Report (RT- PCR)	Active medications	Outco meR- recove red D-
							death
P1	46	М	Mild	Cough, throat pain ,fever	+VE (20-Apr- 2021)	Paracetamol, vit. c, multivitamins, pantoprazole, levocetirizine.	R
P2	30	М	Asympto matic	Cough, throat pain Myalgia, headache	+VE (22-Apr- 2021)	Paracetamol, vit. c, multivitamins, pantoprazole,	R
P3	37	F	Mild	Intermittent fever, Cough, throat pain	+VE(05-	levocetirizine.	R
P4	35	М	Asympto matic	Myalgia, headache Cough, throat pain	May- 2021)	Paracetamol, vit. c, multivitamins, pantoprazole,	R
Р5	35	М			+VE(05- May- 2021)	levocetirizine. Paracetamol, vit.	R
P6	37	F	Asympto matic	Dyspnoea ,nasal obstruction ,fever	-VE(22- Apr-2021)	c, multivitamins, pantoprazole, levocetirizine.	R
P7	36	М	Mild	Cough, throat pain Myalgia, headache	+VE(20- Apr-2021)	Paracetamol, vit. c, multivitamins, pantoprazole,	R
Р8	36	М	Mild	Fever ,headache ,cough.		levocetirizine. Paracetamol, vit.	R
Р9	30	F	Mild	Dyspnoea ,nasal obstruction ,fever	+VE(05- May- 2021)	c, multivitamins, pantoprazole, levocetirizine.	R
P10	65	М	Mild	Myalgia ,throatpain,fever	+VE(05- May- 2021)	Paracetamol, vit. c, multivitamins, pantoprazole, levocetirizine.	R



Asympto		+VE(05-	
matic	Cough , giddiness , cold chills.	May- 2021)	Paracetamol, vit. c, multivitamins, pantoprazole, levocetirizine.
		+VE(05- May- 2021)	Paracetamol, vit. c, multivitamins, pantoprazole, levocetirizine.
			Paracetamol, vit. c, multivitamins, pantoprazole, levocetirizine.



Specific measures/ symptom management

DOI: 10.35629/7781-070512111219 | Impact Factor value 7.429 | ISO 9001: 2008 Certified Journal Page 1214



Clinical severity		Medicines		Dose a	nd timing
Prophylactic care (high risk population, primary contacts)		extract of V	<b>dha</b> (Aqueous Withania IP) or its powder	powder warm v one mo	g extract or 1-3 g r twice daily with water for 15 days or onth or as directed by eda physician
		(Samshamanivati or GiloypowGhana vati having Aqueouswarextract of Tinosporaone		powder warm v one mo	500 mg extract or 1-3 g powder twice daily with warm water for 15 days or one month or as directed by Ayurveda physician
		Chyawana	nprasha		ith warm water / nce a day
Clinical	Clinica		Medicines		Doses & Timing
severity Asymptomatic COVID-19 positive	disease progres sympto	evention of sion to matic and	Guduchi Ghana (Samshamanivati Giloyvati having Aqueous extract of Tinospora cordifo IP) or the powder	or of olia cof	500 mg extract or 1-3 g powder twice daily with warm water for 15 days or one month or as directed by Ayurveda physician
		formand to e recovery	tinospora cordif Guduchi + Pippa (Aqueous extract Tinospora cordife and Piper longum	<b>ali</b> s olia IP	375 mg twice daily with warm water for 15 days or as directed by

In addition to these medicines; general and dietary measures are to be followed.

In addition to these medicines; general and dietary measures are to be followed.



clinical severity	Clinical presentation	Clinical parameters	Medicines	Dose and timing
MILD COVID -19 POSITIVE	SYMPTOMATIC MANAGEMENT Fever Headache Tiredness Dry cough Sore throat Nasal congestion	WITHOUT EVIDENCE OF BREATHLESS- NESSOR HYPOXIA (NORMAL SITUATION)	<b>Guduchi + Pippali</b> (Aqueous extracts Tinospora cordifolia IP and Piper longum IP)	375 mg twice daily with warm water for 15 days or as directed by Ayurveda physician

In addition to these medicines; general and dietary measures are to be followed.

#### Yoga Protocol for Primary Prevention of COVID- 19

- To improve respiratory and cardiac efficiency
- To reduce stress and anxiety
- To enhance immunity

#### Morning Session (30 Minutes)

	Practices	Name of Practice	Rounds	Duration (Minutes)
1	Preparatory Practices (In sitting)	Tadasana		1 min
2		UrdhvaHastottanasana		1min
3		Shoulder rotation	3Round	2min
4		Trunk twisting	3 Round	1min
5		Ardha ustrasana		1min



6	Breathing Practices	Vaataneti	2 Rounds (30 secs/round)	2 min
7		Kapalabhati	3 Rounds (30 secs/round)	2 min
8		Deep Breathing	10 Rounds	2 min
9	Pranayama Practices	Nadishodhana	10 Rounds	6 min
10		Ujjaayee	10 Rounds	3 min
11		Bhramari	10 Rounds	3 min
12	Meditation	Dhyana	AwarenessofbreathingorAwarenessofPositivethoughts/emotions /actionsTotal Duration	6 min 30

#### Management of Mild COVID-19 Cases

Clinical severity	Symptom	Formulation	Dose
	Fever with Body ache, Headache	Nagaradi Kashaya	20 ml twice a day
Mild COVID-	Cough	SitopaladiChurna with honey	with Honey 2 g thrice daily
19	Sore throat, Loss of taste	Vyoshadivati	Chew 1-2 pills as required
	Fatigue	Chyawanprasha	10 g with warm water / milk once a day
	Hypoxia	Vasavaleha	10 g with warm water
	Diarrhoea	Kutaja Ghana Vati 500 mg	1 g thrice daily
	Breathlessness	Kanakasava	10 ml with equal amount of water twice a day



#### General and Physical measures

- Follow physical distancing, respiratory and hand hygiene, wear mask.
- Gargle with warm water added with a pinch of turmeric and salt.
- Nasal instillation/application of medicated oil (Anu taila or Shadbindu Taila) or plain oil (Sesame or Coconut) or nasal application of cow's ghee (Goghrita) once or twice in a day, especially before going out and after coming back to home.
- Steam inhalation with Ajwain (Trachyspermumammi) or Pudina (Mentha spicata) once a day.
- Adequate sleep of 6 to 8 hrs.
- Moderate physical exercises.

#### **Dietary measures**

- Use warm water or boiled with herbs like ginger (Zingiber officinale )or coriander (Coriandrum sativum) or basil (Ocimum sanctum / Ocimumbasilicum), or cumin (Cuminum cyminum) seeds etc., for drinking purpose.
- Fresh, warm, balanced diet.
- Drink Golden Milk (Half tea spoon Haldi (Curcuma longa) powder in 150 ml hot milk) once at night. Avoid in case of indigestion.
- Drink AyushKadha or Kwath (hot infusion or decoction) once a day.

#### Follow up and outcomes:

After diagnosis and till recovery every follow-up was taken telephonically. After positive detection of RTPCR for Covid 19, further investigations were advised, LDH, D-Dimer, CRP, Sr. Ferritin and HRCT. Monitoring of blood pressure, pulse rate, peripheral oxygen saturation was advised. All further follow ups were undertaken telephonically.

The patient recorded and reported the vital check points regularly. Patient tolerated Ayurvedic treatments well and was compliant. Any adverse and unanticipated events were not observed.

#### II. DISCUSSION

The basic concept of disease in Ayurveda has beensaid to be an imbalance of Doshas andderangement of Mandagni(~digestive fire) which leads to a decreased level of immunity and subsequently makingbody susceptible to infectious agents.

The manifestation of this disease can be compared to Sannipatikajwaraespecially of

KaphajaorVatajapredominance where in symptoms such asPratishyaya(~running nose), Kasa(~cough), Tandra(~drowsiness), Aruchi(~decreased appetite), Ajirna(~indigestion),Shirahshula(~headache) are present,

or Shwasa(~breathlessness), Shushka kasa(~dry cough), Mukha shosha(~drynessof mouth) and Atiparshvaruk(~pain in the thoracicregion). The choice of drugs made is to emphasize on improving digestion, protection of respiratory system, and improvizing the bodies' defense.

#### III. CONCLUSION

It is difficult to conclude actual effectiveness of the treatment on the basis of case study, but the results are encouraging enough to conduct more work on COVID- 19 involving Ayurveda. The most significant finding in this study was early negative RTPCR detection, and a restrain observed in the disease progression to rigorous stage. Almost all the symptoms resolved within a period of 11 days. This may pave the way to a more integrated approach toward resolution of the morbidity.

#### **Declaration of patient consent**

The authors certify that they have obtained patient consent form, where the patient/caregiver has given his/her consent for reporting the case along with the images and other clinical information in the journal. The patient/caregiver understands that his/her name and initials will not be published and due efforts will be made to conceal his/her identity, but anonymity cannot be guaranteed.

#### REFERENCES

- [1]. World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report - 1. Geneva: WHO; 2020. [Google Scholar]
- [2]. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - An update on the status. Mil Med Res. 2020;7:11. [PMC free article] [PubMed] [Google Scholar]
- [3]. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [accessed on April 15, 2020].



Available from: <u>https://arcgis/0fHmTX">https://arcg</u> <u>is/0fHmTX</u>.

- [4]. World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report - 46. Geneva: WHO; 2020. [Google Scholar]
- [5]. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China, 2020. China CDC Week. 2020;2:113– 22. [Google Scholar]
- [6]. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20. [PMC free article] [PubMed] [Google Scholar]
- [7]. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 2020;18:20. [PMC free article] [PubMed] [Google Scholar]
- [8]. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance V 12. Geneva: WHO; 2020. [Google Scholar]
- [9]. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020;395:931–4. [PMC free article] [PubMed] [Google Scholar]
- [10]. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177–

9. [PMC free article] [PubMed] [Google Scholar]

- [11]. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623. [PMC free article] [PubMed] [Google Scholar]
- [12]. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020 doi: 101515/cclm-2020-0198. [PubMed] [Google Scholar]
- [13]. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis. 2020;20:425– 34. [PMC free article] [PubMed] [Google Scholar]
- [14]. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497– 506. [PMC free article] [PubMed] [Google Scholar]
- [15]. Ministry of Health & Family Welfare. Guidance document on appropriate management of suspect/confirmed cases of COVID-19. New Delhi: MoHFW, Government of India; 2020. [Google Scholar]
- [16]. Centers for Disease Control and Prevention. Testing COVIDfor 19. [accessed on April 19, 20201. Available from: https://www.cdcgov/coronavirus/201 9-ncov/symptoms-